Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
BOSTON—Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), recently sold 1,404 shares of the company’s common stock. The transaction, which took place on February 18, was valued at approximately $10,881, with shares sold at a price of $7.75 each. The clinical-stage biotech company, currently valued at $397 million, maintains strong liquidity with a current ratio of 12.47x. InvestingPro analysis shows the company holds more cash than debt on its balance sheet.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as disclosed in a footnote accompanying the transaction. It was an automatic sale, not executed at Elazzouzi’s discretion. Following this transaction, Elazzouzi now holds 82,278 shares of Aura Biosciences. With the stock trading near its InvestingPro Fair Value and showing relatively low volatility with a beta of 0.29, investors can access additional insights and 6 more ProTips through InvestingPro’s comprehensive analysis platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.